Moxifloxacin Instead of Isoniazid for Pulmonary TB?

In a multinational trial, rates of culture negativity after 2 months of therapy were similar between the two drugs.

Moxifloxacin has a long serum half-life, causes few problematic drug interactions, and requires no dosage adjustment for renal or hepatic insufficiency. In a mouse model of TB, substitution of moxifloxacin for isoniazid (INH) reduced the time to lung sterilization and allowed therapy to be shortened to 4 months. Could moxifloxacin be substituted for INH in the treatment of active pulmonary TB in humans?

To find out, Tuberculosis Trials Consortium researchers conducted a double-blind trial involving adults during their first 2 months of combination therapy for active pulmonary TB. A total of 328 participants were randomized to receive either moxifloxacin (400 mg) or INH (300 mg) 5 days per week for 8 weeks, in addition to rifampin, pyrazinami…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Moxifloxacin Instead of Isoniazid for Pulmonary TB?

Topics

Reviewing Author